• linkedin
  • Increase Font
  • Sharebar

    FDA approval of retinal dystrophy drug launches era of ocular gene therapy


    Treatment centers designated

    Spark Therapeutics has designated select treatment centers to help ensure the quality of Luxturna from storing and handling to administration. Each treatment center is staffed with healthcare professionals, including retinal specialists, nurses, and genetic counselors, who have experience caring for patients with inherited retinal diseases. (listing available at https://mysparkgeneration.com/hcp-support.html#TreatmentCenters).

    “Our focus is on optimizing patient safety, but providing patient access is also important,” Dr. Falabella. “We took geographic distribution into consideration when selecting the treatment sites.”

    Treating surgeons and pharmacists responsible for preparing the product will be required to undergo educational programs sponsored by Spark Therapeutics.

    In its commitment to help patients gain access to gene therapy, Spark Therapeutics’ patient support program is providing assistance to eligible patients with travel logistics and navigating the complexities of the reimbursement. Cost for Luxturna was set at $425,000 per eye.

    Alex V. Levin, MD, MHSc

    e. [email protected]

    Paulo Falabella, MD

    e. [email protected]

    Dr. Levin is a consultant to Spark Therapeutics. Dr. Falabella is an employee of Spark Therapeutics and shareholder.

    Cheryl Guttman Krader
    Cheryl Guttman is a medical writer based in Deerfield, Ill.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';